Terguride in fluctuating parkinsonian patients

A double-blind study versus placebo

C. Pacchetti, E. Martignoni, P. Bruggi, L. Godi, B. Aufdembrinke, C. Miltenburger, B. Voet, G. Nappi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Terguride (TER), a semisynthetic derivative of lisuride, has been found to display dopamine (DA) agonist and DA antagonist effects in animals, depending on the experimental model used. TER (2 mg/day) was compared to placebo in 41 fluctuating Parkinson's disease patients to test its effect on akinesia and dyskinesia. Mean hours 'off' decreased at weeks 6 and 12 (p <0.05) in the TER group but the overall difference from the placebo group was not significant. Only the TER group displayed a decrease over time in mean Columbia University Rating Scale total score 'on' and 'off' (p = 0.001 and p = 0.03, respectively). Duration of involuntary movements and resulting disability were not significantly different between patients on TER and those on placebo administration. In the overall evaluation, patients preferred TER (p = 0.01). Tolerance of TER was very good in all but one patient whose wearing-off increased, no one dropped out because of side effects. This 3-month double-blind study showed that TER, added to stable doses of L-dopa, may have slight antiparkinsonian efficacy.

Original languageEnglish
Pages (from-to)463-465
Number of pages3
JournalMovement Disorders
Volume8
Issue number4
Publication statusPublished - 1993

Fingerprint

Double-Blind Method
Placebos
Dyskinesias
Lisuride
Antiparkinson Agents
Dopamine Agents
Dopamine Antagonists
dironyl
Dopamine Agonists
Levodopa
Parkinson Disease
Theoretical Models

Keywords

  • Long-term L-dopa syndrome
  • Parkinson's disease
  • Terguride

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Pacchetti, C., Martignoni, E., Bruggi, P., Godi, L., Aufdembrinke, B., Miltenburger, C., ... Nappi, G. (1993). Terguride in fluctuating parkinsonian patients: A double-blind study versus placebo. Movement Disorders, 8(4), 463-465.

Terguride in fluctuating parkinsonian patients : A double-blind study versus placebo. / Pacchetti, C.; Martignoni, E.; Bruggi, P.; Godi, L.; Aufdembrinke, B.; Miltenburger, C.; Voet, B.; Nappi, G.

In: Movement Disorders, Vol. 8, No. 4, 1993, p. 463-465.

Research output: Contribution to journalArticle

Pacchetti, C, Martignoni, E, Bruggi, P, Godi, L, Aufdembrinke, B, Miltenburger, C, Voet, B & Nappi, G 1993, 'Terguride in fluctuating parkinsonian patients: A double-blind study versus placebo', Movement Disorders, vol. 8, no. 4, pp. 463-465.
Pacchetti C, Martignoni E, Bruggi P, Godi L, Aufdembrinke B, Miltenburger C et al. Terguride in fluctuating parkinsonian patients: A double-blind study versus placebo. Movement Disorders. 1993;8(4):463-465.
Pacchetti, C. ; Martignoni, E. ; Bruggi, P. ; Godi, L. ; Aufdembrinke, B. ; Miltenburger, C. ; Voet, B. ; Nappi, G. / Terguride in fluctuating parkinsonian patients : A double-blind study versus placebo. In: Movement Disorders. 1993 ; Vol. 8, No. 4. pp. 463-465.
@article{dba8c5f504174031b951bc25b3f63f6f,
title = "Terguride in fluctuating parkinsonian patients: A double-blind study versus placebo",
abstract = "Terguride (TER), a semisynthetic derivative of lisuride, has been found to display dopamine (DA) agonist and DA antagonist effects in animals, depending on the experimental model used. TER (2 mg/day) was compared to placebo in 41 fluctuating Parkinson's disease patients to test its effect on akinesia and dyskinesia. Mean hours 'off' decreased at weeks 6 and 12 (p <0.05) in the TER group but the overall difference from the placebo group was not significant. Only the TER group displayed a decrease over time in mean Columbia University Rating Scale total score 'on' and 'off' (p = 0.001 and p = 0.03, respectively). Duration of involuntary movements and resulting disability were not significantly different between patients on TER and those on placebo administration. In the overall evaluation, patients preferred TER (p = 0.01). Tolerance of TER was very good in all but one patient whose wearing-off increased, no one dropped out because of side effects. This 3-month double-blind study showed that TER, added to stable doses of L-dopa, may have slight antiparkinsonian efficacy.",
keywords = "Long-term L-dopa syndrome, Parkinson's disease, Terguride",
author = "C. Pacchetti and E. Martignoni and P. Bruggi and L. Godi and B. Aufdembrinke and C. Miltenburger and B. Voet and G. Nappi",
year = "1993",
language = "English",
volume = "8",
pages = "463--465",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Terguride in fluctuating parkinsonian patients

T2 - A double-blind study versus placebo

AU - Pacchetti, C.

AU - Martignoni, E.

AU - Bruggi, P.

AU - Godi, L.

AU - Aufdembrinke, B.

AU - Miltenburger, C.

AU - Voet, B.

AU - Nappi, G.

PY - 1993

Y1 - 1993

N2 - Terguride (TER), a semisynthetic derivative of lisuride, has been found to display dopamine (DA) agonist and DA antagonist effects in animals, depending on the experimental model used. TER (2 mg/day) was compared to placebo in 41 fluctuating Parkinson's disease patients to test its effect on akinesia and dyskinesia. Mean hours 'off' decreased at weeks 6 and 12 (p <0.05) in the TER group but the overall difference from the placebo group was not significant. Only the TER group displayed a decrease over time in mean Columbia University Rating Scale total score 'on' and 'off' (p = 0.001 and p = 0.03, respectively). Duration of involuntary movements and resulting disability were not significantly different between patients on TER and those on placebo administration. In the overall evaluation, patients preferred TER (p = 0.01). Tolerance of TER was very good in all but one patient whose wearing-off increased, no one dropped out because of side effects. This 3-month double-blind study showed that TER, added to stable doses of L-dopa, may have slight antiparkinsonian efficacy.

AB - Terguride (TER), a semisynthetic derivative of lisuride, has been found to display dopamine (DA) agonist and DA antagonist effects in animals, depending on the experimental model used. TER (2 mg/day) was compared to placebo in 41 fluctuating Parkinson's disease patients to test its effect on akinesia and dyskinesia. Mean hours 'off' decreased at weeks 6 and 12 (p <0.05) in the TER group but the overall difference from the placebo group was not significant. Only the TER group displayed a decrease over time in mean Columbia University Rating Scale total score 'on' and 'off' (p = 0.001 and p = 0.03, respectively). Duration of involuntary movements and resulting disability were not significantly different between patients on TER and those on placebo administration. In the overall evaluation, patients preferred TER (p = 0.01). Tolerance of TER was very good in all but one patient whose wearing-off increased, no one dropped out because of side effects. This 3-month double-blind study showed that TER, added to stable doses of L-dopa, may have slight antiparkinsonian efficacy.

KW - Long-term L-dopa syndrome

KW - Parkinson's disease

KW - Terguride

UR - http://www.scopus.com/inward/record.url?scp=0027380410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027380410&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 463

EP - 465

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 4

ER -